yahoo_financeOriginal article
EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)
Phase 3DURAVYUPositive
AI Analysis
Summary
EyePoint Pharmaceuticals has completed enrollment in both pivotal Phase 3 trials of DURAVYU for the treatment of diabetic macular edema, advancing the drug toward potential regulatory submission.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Enrollment completed in both pivotal Phase 3 trials
Importance:6/10
Sentiment:
0.60
Phase 3enrollment completionDMEophthalmology
Related Companies
Read the original article
Published by yahoo_finance on July 30, 2026 11:00 AM